Division Chief, Vascular and Interventional Radiology/Director, Interventional Radiology Center
Johns Hopkins University
USA Vein Clinics and Oncology Centers, United States
Dr. Geschwind is currently the Director of Oncology at USA Vein Clinics where he is responsible for the development of interventional oncology centers.
Dr. Geschwind earned his medical degree from Boston University School of Medicine and completed his residency training in Radiology at the University of California at San Francisco as a Scholar sponsored by the NIH. He pursued his fellowship training in Interventional Radiology at the Johns Hopkins University School of Medicine before joining the faculty. Shortly after, he was appointed Director of Interventional Radiology and promoted to Professor of Radiology, Surgery, and Oncology. While at Johns Hopkins, he concentrated his efforts on treating hepatic cancer and more generally, focused on the nascent field of Interventional Oncology, which he helped develop into a major new field of medicine. He founded the Center of Oncologic Interventions, which utilized new imaging technology partly supported by funding from the NIH to visualize tumors, target them with exquisite precision thereby treating them more effectively. After 19 years at Johns Hopkins, Dr. Geschwind became the Chairman of Radiology and Biomedical Imaging and Professor of Radiology and Medicine (Oncology) at Yale School of Medicine. While there, he created a new research laboratory dedicated to Interventional Oncology and received a major grant from the NIH for research on targeting and imaging of the tumor microenvironment. Dr. Geschwind has published 300 scientific manuscripts in the most highly-rated medical journals, and co-wrote the first textbook dedicated to Interventional Oncology.
Dr. Geschwind is recognized internationally as a key opinion leader in liver cancer and was the lead or co-investigator on 50 clinical trials testing innovative treatments for patients with liver cancer. He also received multiple patents on a new promising drug that targets specific pathways in cancer cells, which allowed him to create a company based on this discovery.